An Open-Label, Multicenter Extension Study to Evaluate the Safety of R935788 in Patients With Rheumatoid Arthritis Who Have Completed the Treatment Phase of a Rigel-Sponsored R935788 Study.
Phase of Trial: Phase II
Latest Information Update: 28 Aug 2014
At a glance
- Drugs Fostamatinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors AstraZeneca; Rigel Pharmaceuticals
- 07 Jun 2017 Biomarkers information updated
- 22 Oct 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 01 Apr 2012 Additional lead trial investigator (Mark Layton) identified as reported by ClinicalTrials.gov.